Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data of sandwich cultured primary rat hepatocytes incubated to piperazine designer drugs

ABSTRACT: The piperazine derivatives most frequently consumed for recreational purposes are 1-benzylpiperazine (BZP), 1-(3,4-methylenedioxybenzyl)piperazine (MDBP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP), and 1-(4-methoxyphenyl)piperazine (MeOPP). Currently it is unclear whether piperazine designer drugs induce mechanisms of hepatotoxicity and, if so, whether they act by a common mechanism. We performed a gene array study with rat hepatocytes incubated with the four designer drugs for 24 h in order to detail the global programme of gene expression

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE68785 | GEO | 2015/05/13

SECONDARY ACCESSION(S): PRJNA283856

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data of sandwich cultured primary rat hepatocytes incubated to piperazine designer drugs

Project description:The piperazine derivatives most frequently consumed for recreational purposes are 1-benzylpiperazine (BZP), 1-(3,4-methylenedioxybenzyl)piperazine (MDBP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP), and 1-(4-methoxyphenyl)piperazine (MeOPP). Currently it is unclear whether piperazine designer drugs induce mechanisms of hepatotoxicity and, if so, whether they act by a common mechanism. We performed a gene array study with rat hepatocytes incubated with the four designer drugs for 24 h in order to detail the global programme of gene expression Primary rat hepatocytes were cultured in collagen sandwich and incubated with the piperazine designer drugs. After 24 h, the RNA was extracted and the Affymetrix microarray analysis was performed.

2015-05-13 | E-GEOD-68785 | biostudies-arrayexpress

A designer peptide against the EAG2-Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma

Project description:This dataset includes the raw single-cell RNAseq data from Xenograft GBM tumor (G411)-bearing NSG mice model treated with either control peptide K59-78TAT or designer peptide K90-114TAT and raw bulk RNAseq data from GBM cell (G411)-neuron coculture model treated with either control peptide K59-78TAT or designer peptide K90-114TAT. In this project, we focused on transcriptomic alteration caused by designer peptide in tumor cells.

2023-06-25 | GSE231577 | GEO

Picky - a simple online method designer for targeted proteomics

Project description:Picky is an online method designer for targeted proteomics. To assess the performance of PRM methods designed by Picky we carried out a benchmark experiment. As reference samples we used different amounts of human proteins spiked into 1.4 µg yeast lysate. These sample where analyzed in PRM and DDA mode. All methods inlcuded a shotgun method (top10 for DDA and top3 for PRM) and can therefore all be analyzed by MaxQuant.

2017-08-04 | PXD007039 | Pride

Trial of Second Generation Designer T Cells in Colorectal Carcinoma

Project description:The purpose of this study is to collect data on the safety and effectiveness of 2nd generation designer T cells in patients with colorectal cancer. Designer T cells are prepared by collecting white blood cells from the participant, and then modifying these cells in the laboratory so that they recognize the tumor antigen (CEA). These modified cells are then given back into the participant so that they can attack and kill tumor cells.

| 2055038 | ecrin-mdr-crc

Repurposing chloramphenicol acetyltransferase for a robust and efficient designer ester biosynthesis platform

Project description:Repurposing chloramphenicol acetyltransferase for a robust and efficient designer ester biosynthesis platform

| MSV000086201 | MassIVE

Correction of a Factor VIII genomic inversion with designer recombinases

Project description:Despite advances in nuclease-based genome editing technologies, correcting human disease-causing genomic inversions remains a challenge. Here, we describe the potential use of a recombinase-based system to correct a 140 kb int1h inversion frequently found in patients diagnosed with Hemophilia A. With the use of directed molecular evolution, we developed a linked heterodimeric recombinase system (RecF8) achieving 30% inversion of the target sequence in human tissue culture cells. Transient RecF8 treatment of endothelial cells, differentiated from int1h patient derived iPSCs, resulted in prominent correction of the inversion and restored Factor VIII mRNA expression. Our data suggest that the development of designer-recombinases represent an efficient and specific mean towards treatment of large gene inversions causing monogenic diseases.

2021-12-31 | GSE159492 | GEO

Correction of a Factor VIII genomic inversion with designer recombinases

Project description:Correction of a Factor VIII genomic inversion with designer recombinases

| PRJNA669049 | ENA

Selective RNA modification in situ by circular gRNAs in designer organelles

Project description:Selective RNA modification in situ by circular gRNAs in designer organelles

| PRJEB76145 | ENA

Functional Optimization of Designer Cardiac Organoids Enabled by Machine Learning Techniques

Project description:Functional Optimization of Designer Cardiac Organoids Enabled by Machine Learning Techniques

| PRJNA1111511 | ENA

Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors

Project description:Ovarian cancer is the leading cause of death among gynecological malignancies. It is usually detected at late stages when the disease is spread through the abdominal cavity in form of ascitic fluids. Thus, there is an urgent need to develop novel therapeutic interventions to target advanced stages of ovarian cancer, particularly metastatic disease. Mammary serine protease inhibitor (Maspin) represents an important metastasis suppressor initially identified in breast cancer. In this work we have generated a sequence-specific zinc finger artificial transcription factor (ATF) to up-regulate the Maspin promoter in aggressive ovarian cancer cell lines, to interrogate the therapeutic potential of Maspin in ovarian cancer. We found that while Maspin was expressed in some primary ovarian tumors, the promoter was epigenetically silenced in cell lines derived from ascites. Transduction of the ATF in MOVCAR 5009 cells derived from ascitic cultures of a TgMISIIR-Tag mouse model of ovarian cancer resulted in tumor cell growth, impaired cell invasion, and severe disruption of actin cytoskeleton. Systemic delivery of lipid-protamine-RNA (LPR) nanoparticles encapsulating a chemically modified ATF mRNA resulted in inhibition of ovarian cancer cell growth in nude mice, accompanied with Maspin re-expression in the treated tumors. Finally, gene expression microarrays of ATF-transduced cells revealed an exceptional potency and specificity for the Maspin promoter. These analyses revealed targets co-regulated with Maspin in human short-term cultures derived from ascitic fluids from ovarian cancer patients, such as TSPAN12, which could mediate the anti-metastatic phenotype of the ATF. Our work outlined the first targeted, non-viral delivery of designer ATFs into tumors with potential application in clinical trials for metastatic ovarian cancers. reference X sample with 6 samples

2012-09-29 | E-GEOD-36396 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data